Marpai, Inc. in brief
Marpai, Inc. is a listed company in the Healthcare sector, based in Tampa, Florida, USA. Its last known market value was $14 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $18 M and a net loss of $17 M. It employs about 107 people. Its largest product and service lines by sales in 2025 were Third party administrator services (100%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Marpai, Inc.
We are a technology platform company which operates subsidiaries that provide Third Party Administrator, Pharmacy Benefit Management, and value-oriented health plan services to employers that directly pay for employee health benefits. Our mission is to positively change healthcare for the benefit of (i) our Clients who are self-insured employers that pay for their employees’ healthcare benefits and engage us to administer the latter’s healthcare claims, and we refer to them as our “Clients”, (ii) employees and their family members who receive these healthcare benefits from our Clients, and we refer to them as our “Members”, and (iii) healthcare providers including, doctors, doctor groups, hospitals, clinics, and any other entities providing healthcare services or products, and we refer to them as the “Providers.” We provide affordable, intelligent, healthcare programs for self-insured employers in the U.S. We provide administrative services, and act as TPA to self-insured employers who provide healthcare benefits to their employees. Most of our Clients are small and medium-sized companies as well as local government entities.
From the company's annual report filed with the US SEC: read the report
Marpai, Inc. timeline
- 2021
- 🔔· approximateInitial public offering
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2023
- 💰Record revenue of $37 millionFY2023, the highest of the 5 years on record.
Events of Marpai, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,354 (Dec 2022) · #5,344 (Jul 2023) · #4,446 (Jan 2024)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- -98.1%
- Operating margin
- -74.9%
- Return on equity
- —
- Liabilities / assets
- 398.8%
- Net debt
- $19M
- Revenue growth
- -35.7%
- R&D / revenue
- 0.1%
- Revenue per employee
- $169 K
- Profit per employee
- $-155 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $18M | -35.7% | $-14M | $-17M | -91.5% |
| Dec 2024 | $28M | -24.2% | $-22M | $-22M | -78.4% |
| Dec 2023 | $37M | +52.7% | $-28M | $-29M | -77.4% |
| Dec 2022 | $24M | +71.0% | $-27M | $-26M | -108.8% |
| Dec 2021 | $14M | — | $-16M | $-16M | -112.3% |
| Dec 2020 | — | — | $-3M | $-4M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-7M | — | — | $-0.95 | — |
| Dec 2024 | $-15M | — | — | $-1.92 | — |
| Dec 2023 | $-16M | — | — | $-4.14 | — |
| Dec 2022 | $-35M | $0M | $-36M | $-5.23 | — |
| Dec 2021 | $-11M | $0M | $-11M | $-1.59 | — |
| Dec 2020 | $-2M | $0M | $-2M | $-1.60 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $4M (+9.4% on a year earlier), net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Oct 23, 2026DEF 14AProxy statement
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Jul 31, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Bylaws amended · Other events
- Jul 20, 20268-KCurrent reportMaterial agreement · Other events
- May 15, 202610-QQuarterly report · period to Mar 2026
- May 1, 20268-KCurrent reportMaterial agreement
- Mar 25, 202610-KAnnual report · period to Dec 2025
- Mar 11, 20268-KCurrent reportMaterial agreement · New financial obligation
- Feb 13, 20268-KCurrent reportMaterial agreement · New financial obligation
- Jan 23, 20268-KCurrent reportDirectors or officers changed
- Dec 23, 20258-KCurrent reportMaterial agreement · Unregistered share sale
Official filings of Marpai, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $18 M
- Operating income
- $-14 M
- Net income
- $-17 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $43 M
- Total equity
- $-33 M
As of December-2025
Insider trading at Marpai, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Steve Andrew JohnsonChief Financial Officer | Buy | +1,100 | $0.620 | $682 | 1.02 M | Form 4 |
| filed | Colleen DiClaudioDirector | Grant or award10b5-1 plan | +125,000 | — | — | 267,500 | Form 4 |
| filed | Steve Andrew JohnsonChief Financial Officer | Grant or award | +125,000 | — | — | 1.02 M | Form 4 |
| filed | Damien LamendolaChief Executive Officer, Director, 10% owner | Grant or award | +300,000 | — | — | 1.65 M | Form 4 |
| filed | Robert M. PonsDirector | Grant or award | +100,000 | — | — | 484,200 | Form 4 |
| filed | Yaron EitanDirector | Grant or award | +175,000 | — | — | 1.22 M | Form 4 |
| filed | Sagiv ShivDirector | Grant or award10b5-1 plan | +125,000 | — | — | 613,667 | Form 4 |
| filed | Jennifer Rosario CalabreseDirector | Grant or award10b5-1 plan | +100,000 | — | — | 225,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Marpai, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-4 reverse split ; 4.556-for-1 split
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Marpai, Inc. scorecard#
Passes 1 of the 12 checks that could be worked out: strongest in profitability (1 of 4), weakest in growth (0 of 5). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 5
- ✗Revenue grew in the newest year-35.8%Revenue down 35.8% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-9.4%-9.4% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-9.4%-9.4% a year against Healthcare's median of 8.5% (549 companies).
- ✗Earnings per share grew in the newest year-0.95 vs -1.92Diluted EPS -0.95 in fiscal 2025 against -1.92 the year before (report's currency).
- ✗Net income higher than five years earlier-$17 M-$17 M in fiscal 2025 against -$4 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 4
- ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-74.9%-74.9% against Healthcare's median of -7.7% (674 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-74.9%-74.9% in fiscal 2025 against -110.8% in 2022.
Financial health0 of 2
- ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.40 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year50.9%Diluted shares up 50.9% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Marpai, Inc.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -74.9% | -7.7% | |
| Net margin | -91.5% | -8.1% | |
| Revenue growth, 3 years a year | -9.4% | 8.5% | |
| Revenue growth | -35.8% | 10.2% |
3of 8on the Piotroski tests of financial strength
- Revenue fell 35.8% against the year before.
- Net loss of $17 million, the 6th loss-making year in a row.
- The share count rose 50.9% in the year.
- Shareholders' equity is negative: -$33 million.
Marpai, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 18−35.8%100% | 28−24.2%100% | 37r37+52.6%100% | 24+71.1%100% | 14—100% | — | |
| Research and development | 0.0−75.9%0.0% | 0.0−97.8%0.1% | 1.3r1.3−64.6%3.5% | 3.7+114%15.2% | 1.7−1.8%12.2% | 1.8—— | |
| Selling and marketing | 1.1−38.2%6.0% | 1.8−73.2%6.3% | 6.6r6.6−4.9%17.8% | 6.9+39.7%28.5% | 5.0+17901%34.9% | 0.0—— | |
| General and administrative | 11−13.2%61.5% | 13−33.1%45.5% | 19r19+55.7%51.6% | 12+52.9%50.6% | 8.1+437%56.6% | 1.5—— | |
| Total costs and expenses | 32−37.0%175% | 50−22.8%178% | 65r65+27.0%175% | 51+70.5%211% | 30+793%211% | 3.4—— | |
| Operating income | −14—−74.9% | −22—−78.4% | −28r−28—−75.3% | −27—−111% | −16—−111% | −3.4—— | |
| Interest expense and finance costs | 3.2+19.4%17.9% | 2.7+77.4%9.6% | 1.5r1.5+472%4.1% | 0.3−37.5%1.1% | 0.4−18.0%3.0% | 0.5—— | |
| Other non-operating income (expense) | — | 0.4−18.9%1.4% | 0.5r0.5+108%1.3% | 0.2+35.9%1.0% | 0.2+567%1.2% | 0.0—— | |
| Income before tax | −17—−91.5% | −23—−82.6% | −29r−29—−78.2% | −27—−111% | −16—−113% | −3.9—— | |
| Income tax | — | −1.2—−4.2% | −0.3r−0.3—−0.8% | −0.5—−2.1% | −0.2—−1.1% | — | |
| Net income including minority interests | — | — | −29—−77.4% | −26—−109% | −16—−112% | −3.9—— | |
| Net income attributable to shareholders | −17—−91.5% | −22—−78.4% | −29r−29—−77.4% | −26—−109% | −16—−112% | −3.9—— | |
| Earnings per share, basic | -0.95—— | -1.92—— | -4.14—— | -5.23r-1.31—— | -1.59—— | -1.60—— | |
| Earnings per share, diluted | -0.95—— | -1.92—— | -4.14—— | -5.23r-1.31—— | -1.59—— | -1.60—— | |
| Shares, weighted average (basic) | 17+50.9%— | 12+65.6%— | 7.0+37.4%— | 5.1r20−49.8%— | 10+315%— | 2.4—— | |
| Shares, weighted average (diluted) | 17+50.9%— | 12+65.6%— | 7.0+37.4%— | 5.1r20−49.8%— | 10+315%— | 2.4—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 0.1−82.6%1.2% | 0.8−33.4%5.9% | 1.1r1.1−91.7%3.6% | 14−28.2%27.6% | 19+993%43.4% | 1.8—26.9% | |
| Receivables | 0.7−16.7%6.4% | 0.8−25.5%6.5% | 1.1r1.1−21.8%3.5% | 1.4+589%2.9% | 0.2—0.5% | — | |
| Other current assets | 0.4−46.2%3.7% | 0.8−15.8%5.9% | 0.9r0.9−43.8%2.8% | 1.6+116%3.2% | 0.7+183%1.7% | 0.3—4.0% | |
| Current assets | 10−13.1%94.8% | 12−30.4%92.4% | 17r17−35.6%53.9% | 27−1.7%53.1% | 27+1138%61.1% | 2.2—33.4% | |
| Property, plant and equipment | 0—0.0% | 0−100%0.0% | 0.6r0.6−59.4%1.9% | 1.5+69.2%3.0% | 0.9+355%2.0% | 0.2—3.0% | |
| Right-of-use (leased) assets | 0.2−26.4%2.0% | 0.3−87.5%2.3% | 2.4r2.4−38.2%7.5% | 3.8+88.0%7.7% | 2.0+506%4.6% | 0.3—5.2% | |
| Goodwill | — | — | 3.0r3.00.0%9.5% | 3.0r5.8+26.7%6.0% | 2.4—5.4% | — | |
| Other intangible assets | 0.1−86.4%0.6% | 0.4−91.5%3.4% | 5.2r5.2−18.1%16.3% | 6.3+14.8%12.7% | 5.5—12.5% | — | |
| Total assets | 11−15.3%100% | 13−59.3%100% | 32r32−36.6%100% | 50+13.0%100% | 44+577%100% | 6.5—100% | |
| Accounts payable | 3.7+18.0%33.6% | 3.1−33.1%24.1% | 4.6r4.6+219%14.7% | 1.5+29.5%2.9% | 1.1+607%2.5% | 0.2—2.4% | |
| Debt due within a year | 8.0—73.4% | — | — | — | — | — | |
| Current liabilities | 26+35.4%236% | 19−8.9%147% | 21r21+20.1%65.8% | 17+55.8%34.8% | 11+321%25.2% | 2.6—40.6% | |
| Long-term debt | 11—105% | — | — | — | — | — | |
| Lease liabilities (non-current) | 0.5−33.4%4.8% | 0.8−78.5%6.2% | 3.7r3.7−22.8%11.6% | 4.8+267%9.6% | 1.3+360%2.9% | 0.3—4.3% | |
| Total liabilities | 43+7.1%399% | 41−10.0%315% | 45r45+3.0%142% | 44+202%87.7% | 14+44.5%32.8% | 10—154% | |
| Retained earnings | −115—−1058% | −99—−767% | −77—−242% | −48—−96.1% | −22—−48.7% | −5.5—−84.8% | |
| Shareholders' equity | −33—−299% | −28—−215% | −13r−13−319%−42.4% | 6.1r6.1−79.3%12.3% | 30—67.2% | −3.5—−53.5% | |
| Total liabilities and equity | 11−15.3%100% | 13−59.3%100% | 32r32−36.6%100% | 50+13.0%100% | 44+577%100% | 6.5—100% | |
| Shares outstanding | 24+68.8%— | 14+78.8%— | 8.0+49.6%— | 5.3r21−73.8%— | 20+14159%— | 0.1—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.4−83.1%2.1% | 2.3−42.1%8.0% | 3.9+10.1%10.5% | 3.5+80.4%14.5% | 2.0+2537%13.8% | 0.1—— | |
| Share-based compensation | 3.6+14.5%20.0% | 3.2+50.4%11.2% | 2.1r2.1−32.4%5.6% | 3.1+152%12.8% | 1.2+19.4%8.7% | 1.0—— | |
| Cash from operating activities | −7.5—−41.2% | −15—−53.8% | −16r−16—−42.4% | −35—−145% | −11—−75.9% | −1.9—— | |
| Capital expenditure | — | — | — | −0.4—−1.5% | −0.3—−1.9% | −0.0—— | |
| Intangible assets bought | — | — | — | — | −0.0—−0.0% | — | |
| Cash from investing activities | 0.5+120%2.8% | 0.2−77.9%0.8% | 1.0r1.0−96.8%2.8% | 32+236%133% | 9.6—67.8% | −0.6—— | |
| Shares issued | 7.0+50.9%38.8% | 4.7−27.5%16.5% | 6.4r6.4—17.3% | — | — | — | |
| Cash from financing activities | 6.7−37.5%36.9% | 11+109%37.9% | 5.1r5.1+2599900%13.7% | 0.0−100.0%0.0% | 25+520%178% | 4.1—— | |
| Change in cash | — | — | −9.6—−25.9% | −2.8−112%−11.6% | 24+1434%170% | 1.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 17−17.8%100% | 4.4+9.6%100% | 4.2−10.5%100% | 4.4−18.0%100% | 4.0*−39.5%100% | 4.0−42.4%100% | 4.7−35.2%100% | 5.4−26.6%100% | 6.6*−24.3%100% | 7.0—100% | 7.2—100% | 7.4—100% | 8.7r8.7*—100% | |
| Research and development | — | — | — | — | 0*−100%0.0% | 0*−100%0.0% | 0*−100%0.0% | 0.00.0%0.1% | 0.0*−65.0%0.1% | 0.0—0.1% | 0.0—0.1% | 0.0—0.1% | 0.0r0.0*—0.2% | |
| Selling and marketing | 0.8−38.9%4.4% | 0.1−49.5%3.4% | 0.1−56.4%3.3% | 0.2−6.5%5.2% | 0.2*−37.3%6.0% | 0.3−14.5%7.3% | 0.3−28.4%6.7% | 0.2−59.3%4.5% | 0.4*−65.3%5.8% | 0.3—4.9% | 0.4—6.1% | 0.6—8.2% | 1.1r1.1*—12.7% | |
| General and administrative | 12+19.9%68.4% | 2.1+3.3%48.3% | 3.1+23.6%73.7% | 2.1−6.7%47.9% | 4.3*+49.6%108% | 2.1−26.5%51.2% | 2.5−33.3%53.3% | 2.3−33.3%42.1% | 2.9*−11.1%43.7% | 2.8—40.1% | 3.7—51.8% | 3.4—46.3% | 3.2r3.2*—37.2% | |
| Total costs and expenses | 30−5.1%178% | 6.9+1.8%157% | 7.6−8.0%182% | 6.9−9.7%156% | 8.9*−3.9%224% | 6.8−32.4%169% | 8.3−57.5%177% | 7.7−33.0%142% | 9.3*−33.1%141% | 10—144% | 19—271% | 11—155% | 14r14*—159% | |
| Operating income | −13—−78.4% | −2.5—−56.6% | −3.4—−82.4% | −2.5—−55.9% | −4.9*—−124% | −2.8—−68.6% | −3.6—−77.5% | −2.3—−41.5% | −2.7*—−40.8% | −3.1—−43.7% | −12—−171% | −4.1—−55.0% | −5.2r−5.2*—−59.2% | |
| Interest expense and finance costs | 3.7+12.8%21.5% | 0.9+7.5%19.4% | 1.2+50.9%29.5% | 0.8−5.4%17.4% | 0.8*−1.8%20.2% | 0.8+28.5%19.7% | 0.8−6.8%17.5% | 0.8+106%15.1% | 0.8*+92.7%12.4% | 0.6—8.8% | 0.9—12.1% | 0.4—5.4% | 0.4r0.4*—4.9% | |
| Other non-operating income (expense) | — | — | — | — | — | — | — | — | 0.0*−86.0%0.5% | 0.1—1.7% | 0.1—1.7% | 0.1—1.6% | 0.3r0.3*—3.0% | |
| Income before tax | −17—−98.0% | −3.3—−74.3% | −4.6—−110% | −3.2—−71.6% | −5.6*—−141% | −3.5—−86.5% | −4.4—−93.9% | −3.1—−56.6% | −2.3*—−35.6% | −3.6—−50.8% | −13—−181% | −4.3—−58.8% | −5.3r−5.3*—−61.1% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | −4.3—−58.8% | −5.0*—−57.7% | |
| Net income attributable to shareholders | −17—−98.0% | −3.3—−74.3% | −4.6—−110% | −3.2—−71.6% | −5.6*—−141% | −3.5—−86.5% | −4.4—−93.9% | −3.1—−56.6% | −1.2*—−17.5% | −3.6—−50.8% | −13—−181% | −4.3—−58.8% | −5.0r−5.0*—−57.7% | |
| Earnings per share, basic | — | -0.13—— | -0.18—— | -0.13—— | — | -0.20—— | -0.28—— | -0.21—— | — | -0.30—— | -1.23—— | -0.46—— | — | |
| Earnings per share, diluted | — | -0.13—— | -0.18—— | -0.13—— | — | -0.20—— | -0.28—— | -0.21—— | — | -0.30—— | -1.23—— | -0.46—— | — | |
| Shares, weighted average (basic) | 27+55.1%— | 27+55.1%— | 26+66.8%— | 25+67.1%— | — | 17+43.6%— | 16+45.9%— | 15+57.0%— | — | 12—— | 11—— | 9.4—— | — | |
| Shares, weighted average (diluted) | 27+55.1%— | 27+55.1%— | 26+66.8%— | 25+67.1%— | — | 17+43.6%— | 16+45.9%— | 15+57.0%— | — | 12—— | 11—— | 9.4—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 0.4—3.3% | 0.4−19.1%3.3% | 0.1−77.7%1.5% | 0.2−72.4%1.8% | 0.1−82.6%1.2% | 0.4−46.4%3.5% | 0.6−52.1%5.6% | 0.7−14.3%5.3% | 0.8−33.4%5.9% | 0.8—4.2% | 1.3—5.8% | 0.9—2.8% | 1.1r1.1—3.6% | |
| Receivables | 0.9—8.7% | 0.9+149%8.7% | 1.0+85.6%10.7% | 0.7+101%6.8% | 0.7−16.7%6.4% | 0.4−69.3%3.0% | 0.5−31.9%5.0% | 0.4+0.5%2.7% | 0.8−25.5%6.5% | 1.2—6.3% | 0.8—3.6% | 0.4—1.2% | 1.1r1.1—3.5% | |
| Other current assets | 0.3—3.2% | 0.3−12.6%3.2% | 0.3−44.6%3.5% | 0.4−40.8%3.3% | 0.4−46.2%3.7% | 0.4−48.5%3.1% | 0.6−39.0%5.3% | 0.6−38.5%4.5% | 0.8−15.8%5.9% | 0.8—3.9% | 1.0—4.4% | 1.0—3.3% | 0.9r0.9—2.8% | |
| Current assets | 10—95.9% | 10−14.2%95.9% | 9.0−12.9%95.1% | 10−18.9%95.6% | 10−13.1%94.8% | 12−18.8%94.7% | 10−39.9%93.4% | 13−22.0%93.8% | 12−30.4%92.4% | 15—75.9% | 17—77.4% | 17—54.9% | 17r17—53.9% | |
| Property, plant and equipment | — | — | — | — | 0—0.0% | — | — | — | 0−100%0.0% | 0.5—2.6% | 0.5—2.5% | 0.6—1.9% | 0.6r0.6—1.9% | |
| Right-of-use (leased) assets | 0.2—1.7% | 0.2−28.7%1.7% | 0.2−27.2%2.0% | 0.2−26.7%1.9% | 0.2−26.4%2.0% | 0.3−88.5%2.0% | 0.3−88.2%2.4% | 0.3−87.8%2.0% | 0.3−87.5%2.3% | 2.2—11.2% | 2.3—10.1% | 2.3—7.7% | 2.4r2.4—7.5% | |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | 3.0—10.0% | 3.0r3.0—9.5% | |
| Other intangible assets | — | — | — | — | 0.1−86.4%0.6% | — | — | — | 0.4−91.5%3.4% | — | — | 4.9—16.2% | 5.2r5.2—16.3% | |
| Total assets | 11—100% | 11−15.2%100% | 9.5−14.4%100% | 11−20.4%100% | 11−15.3%100% | 13−35.0%100% | 11−50.2%100% | 14−54.4%100% | 13−59.3%100% | 20—100% | 22—100% | 30—100% | 32r32—100% | |
| Accounts payable | 2.7—24.9% | 2.7−39.0%24.9% | 5.8+61.2%61.1% | 5.9+116%54.1% | 3.7+18.0%33.6% | 4.4+17.2%34.6% | 3.6+13.1%32.4% | 2.7−28.5%19.9% | 3.1−33.1%24.1% | 3.8—19.2% | 3.2—14.3% | 3.8—12.7% | 4.6r4.6—14.7% | |
| Customer deposits | — | — | — | — | — | — | — | — | — | — | 5.0—22.5% | — | — | |
| Debt due within a year | — | — | 2.5−12.8%25.9% | 8.0+185%73.3% | 8.0—73.4% | 2.8—22.0% | 2.8—25.4% | 2.8—20.5% | — | — | — | — | — | |
| Current liabilities | 16—147% | 16−30.4%147% | 24+19.3%249% | 27+37.1%249% | 26+35.4%236% | 23+25.3%179% | 20+5.6%178% | 20−1.6%144% | 19−8.9%147% | 18—92.7% | 19—84.1% | 20—66.9% | 21r21—65.8% | |
| Long-term debt | 19—174% | 19+16.2%174% | 18+16.5%193% | 12−22.1%109% | 11—105% | 16—127% | 16—142% | 15—111% | — | — | — | — | — | |
| Lease liabilities (non-current) | 0.3—2.9% | 0.3−47.7%2.9% | 0.4−42.2%4.1% | 0.5−37.4%4.2% | 0.5−33.4%4.8% | 0.6−81.6%4.7% | 0.7−80.5%6.0% | 0.7−79.4%5.3% | 0.8−78.5%6.2% | 3.3—16.6% | 3.4—15.3% | 3.5—11.8% | 3.7r3.7—11.6% | |
| Total liabilities | 41—375% | 41−12.0%375% | 48+11.4%511% | 46+5.1%423% | 43+7.1%399% | 46−2.3%361% | 43−9.3%393% | 44−1.5%320% | 41−10.0%315% | 47—241% | 48—216% | 45—148% | 45r45—142% | |
| Retained earnings | −126—−1169% | −126—−1169% | −123—−1301% | −119—−1086% | −115—−1058% | −110—−861% | −106—−961% | −102—−743% | −99—−767% | −98—−498% | −94—−424% | −81—−270% | −77—−242% | |
| Shareholders' equity | −30—−275% | −30—−275% | −39—−411% | −35—−323% | −33—−299% | −33—−261% | −32—−293% | −30—−220% | −28—−215% | −28—−141% | −26—−116% | −14—−48.2% | −13r−13—−42.4% | |
| Total liabilities and equity | 11—100% | 11−15.2%100% | 9.5−14.4%100% | 11−20.4%100% | 11−15.3%100% | 13−35.0%100% | 11−50.2%100% | 14−54.4%100% | 13−59.3%100% | 20—100% | 22—100% | 30—100% | 32r32—100% | |
| Shares outstanding | 27—— | 27+45.6%— | 27+61.3%— | 25+69.8%— | 24+68.8%— | 18+34.2%— | 17+49.8%— | 15+44.5%— | 14+78.8%— | 14—— | 11—— | 10—— | 8.0—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1−76.0%0.7% | 0*−100%0.0% | 0*−100%0.0% | 0.1−43.9%1.4% | 0.1*−66.3%1.5% | 0.1−49.8%2.7% | 0.1−88.3%2.3% | 0.1−88.7%2.0% | 0.2*−80.7%2.7% | 0.2—3.0% | 0.9—12.7% | 1.0—12.9% | 0.9*—10.6% | |
| Share-based compensation | 3.4+241%20.0% | 0.1*+500%3.0% | 0.9*+2679%22.0% | 0.2−64.6%4.6% | 2.2*+481%54.1% | 0.0−71.1%0.5% | 0.0−64.9%0.7% | 0.6+2.3%10.6% | 0.4*+41.6%5.6% | 0.1—1.1% | 0.1—1.3% | 0.6—7.6% | 0.3r0.3*—3.0% | |
| Cash from operating activities | −16—−95.9% | −7.0*−1201%−158% | −4.1*—−98.4% | −0.5—−10.7% | −4.8*—−119% | 0.6*—15.7% | −3.2*—−68.9% | −0.1—−2.1% | −4.7r−4.9*—−71.0% | −3.8r−3.5*—−53.8% | −3.1*—−43.4% | −3.6—−48.5% | −0.4r−0.4*—−4.9% | |
| Cash from investing activities | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | 0.5—9.2% | 0*−100%0.0% | — | — | — | 1.0r1.0*—11.5% | |
| Shares issued | — | — | — | — | 4.2*+562%105% | 2.1*+61.7%52.0% | — | — | 0.6*—9.6% | 1.3*—18.5% | 0*—0.0% | 2.7—36.9% | 0r0*—0.0% | |
| Cash from financing activities | 14+143%79.8% | 8.2*+411%185% | 2.0*—49.0% | 0.2−91.5%3.6% | 3.2*+52.0%80.2% | 1.6*+23.2%39.7% | −0.0*−101%−0.4% | 1.9−48.9%34.9% | 2.1*—31.9% | 1.3*—18.5% | 3.6*—49.6% | 3.7—50.2% | −1.3r−1.3*—−15.3% | |
| Change in cash | — | — | — | — | — | — | — | — | — | — | — | 0.1—1.6% | −0.8*—−8.7% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Marpai, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Third party administrator services$18 M100%-36%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Marpai, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chief executive | $1.2 M | $1.2 M | $1.3 M | $19 |
| 2024Chief executive | $362 K | $712 K | $514 K | $25 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Marpai, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 3 · Material agreement 15 · New debt 3 · Unregistered share sale 10 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Material agreementUnregistered share saleBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementNew debt | 8-K | |
| Directors and officers | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Jul 31, 2026
How Marpai, Inc. compares in Healthcare
- Revenue$18 M · higher than 26% of 1,795
- Net margin-98.1% · higher than 17% of 1,485
- Revenue growth-35.8% · higher than 13% of 1,003
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Marpai, Inc.🇺🇸 | $14 M | — | -98.1% | -35.8% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- UnitedHealth Group Incorporated$367.7 B
- Merck & Co., Inc.$359.8 B
Sources and freshness
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Marpai, Inc.? Verify and update this profile — free
Show Marpai, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.